In contrast, pathways predicted to be inhibited in R vs. NR patients included the “PD-1, PD-L1 cancer immunotherapy”, the “MSP-RON signaling in macrophages” and the “GP6 signaling” pathways. The gene discussed is PDCD1; the disease is cancer.